As of 2025-09-15, the Fair Value of GT Biopharma Inc (GTBP) is -16.39 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.81 USD, the upside of GT Biopharma Inc is -2,136.43%.
With the market price of 0.81 USD and our fair value calculation, GT Biopharma Inc (GTBP) is not a good investment. Investing in GTBP stocks now will result in a potential loss of 2,136.43%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -28.30 | -58.01 | -20.88 | -7.60 | -13.16 | -25.59 |
| YoY growth | 26.78% | -105.02% | 64.00% | 63.62% | -73.25% | -4.77% |
| Market Cap (mil) | 2.87 |
| P/E | |
| Forward P/E |
| EPS | -3.28 |
| Avg earnings growth rate | -4.77% |
| TTM earnings | -11.67 |